Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment
Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment
Purpose
Combination treatment of inhaled corticosteroid (ICS) plus long-acting ?2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the ?2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA.
Materials and Methods
43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 µg/day) plus terbutaline (5 µg prn). as needed. During the 24-week active treatment period, they received budesonide 160 µg and formoterol 4.5 µg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology.
Results
During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients.
Conclusion
Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.
182-188
Kim, S.H.
1e5e8a15-6524-419a-b2f9-73e9653de401
Ye, Y.M.
173a9d18-0493-4e4a-a08d-cac83cc9711f
Hur, G.Y.
3bf49a50-fb25-4a81-b141-07410cd6a6d0
Lee, H.Y.
43b45c39-d1f0-4778-a049-883b907bf48d
Jee, Y.K.
fb8bd10c-de22-4fd5-a34f-8c9c66a41024
Lee, S.H.
104039b1-5d0a-4175-9a03-55a52132be2b
Holloway, J.W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
Park, H.S.
37395c90-bc75-4c48-9d46-daac0107844b
April 2009
Kim, S.H.
1e5e8a15-6524-419a-b2f9-73e9653de401
Ye, Y.M.
173a9d18-0493-4e4a-a08d-cac83cc9711f
Hur, G.Y.
3bf49a50-fb25-4a81-b141-07410cd6a6d0
Lee, H.Y.
43b45c39-d1f0-4778-a049-883b907bf48d
Jee, Y.K.
fb8bd10c-de22-4fd5-a34f-8c9c66a41024
Lee, S.H.
104039b1-5d0a-4175-9a03-55a52132be2b
Holloway, J.W.
4bbd77e6-c095-445d-a36b-a50a72f6fe1a
Park, H.S.
37395c90-bc75-4c48-9d46-daac0107844b
Kim, S.H., Ye, Y.M., Hur, G.Y., Lee, H.Y., Jee, Y.K., Lee, S.H., Holloway, J.W. and Park, H.S.
(2009)
Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.
Yonsei Medical Journal, 50 (2), .
(doi:10.3349/ymj.2009.50.2.182).
Abstract
Purpose
Combination treatment of inhaled corticosteroid (ICS) plus long-acting ?2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the ?2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA.
Materials and Methods
43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 µg/day) plus terbutaline (5 µg prn). as needed. During the 24-week active treatment period, they received budesonide 160 µg and formoterol 4.5 µg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology.
Results
During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients.
Conclusion
Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.
This record has no associated files available for download.
More information
Published date: April 2009
Identifiers
Local EPrints ID: 69837
URI: http://eprints.soton.ac.uk/id/eprint/69837
PURE UUID: 3c15c8e2-971d-4eb1-95c7-53fac616216c
Catalogue record
Date deposited: 08 Dec 2009
Last modified: 14 Mar 2024 02:41
Export record
Altmetrics
Contributors
Author:
S.H. Kim
Author:
Y.M. Ye
Author:
G.Y. Hur
Author:
H.Y. Lee
Author:
Y.K. Jee
Author:
S.H. Lee
Author:
H.S. Park
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics